Justin Verlander threw his first big-league pitch on July 4, 2005, when a 200-inning season was still a job description. Twenty-one years and 557 starts later, he took the mound for the last time at 43. He and Max Scherzer, the oldest men in the game, spent the closing weeks of the 2026 season making a case to The Athletic: save the starter. Few pitchers have more standing to say it. Verlander returned from Tommy John surgery in his late 30s and kept taking the ball, and Scherzer built a reputation on glaring at managers who came to take it from him. Their plea lands in a sport where starters rarely see a lineup a third time and bullpens cycle arms like a call center cycling shifts. Two survivors make a thin sample, though, and before you adopt their lesson it helps to know what is breaking in everyone else.
Most arguments about the plea run on temperament, pitting old-school toughness against analytics departments that pull starters early for defensible reasons. Both camps skip the mechanism. A pitcher's durability rests on one strip of tissue under repeated strain, and the sport pays for that strain at every level, from Little League diamonds to nine-figure contracts. Leave that out and "save the starter" sounds like a request for more grit, and grit has never sewn a ligament back together. The question that matters is who gets paid when an elbow wears out early. Answer it, and you can tell whether two 40-something aces are describing a solution or describing their own luck.
Jeff Passan's The Arm opens on an unglamorous piece of anatomy: the ulnar collateral ligament, a band of tissue in the elbow roughly the size of a rubber band. A starting pitcher's career can hinge on it. When it tears, the usual answer is Tommy John surgery, and Passan spent three years reporting on why that answer has become routine everywhere from youth fields to the richest contracts in the game. His method is to follow the arm through time and across borders. The history traces how a once-radical operation hardened into a rite of passage.
Passan secured a rare interview with Sandy Koufax, whose elbow ended one of the great careers when he was 30, and he traveled to Japan to see how another baseball-obsessed country guards its prized arms. Pitchers like Yu Darvish and Shota Anraku figure into that thread, which turns on how much work a young thrower should absorb and who gets to decide. The closest reporting follows major leaguers Daniel Hudson and Todd Coffey through surgery and rehabilitation. These chapters dwell on the slow months of throwing progressions and on the open question of whether a rebuilt elbow will hold.
It is a strange kind of waiting for men whose whole trade happens in half a second, and Passan renders the boredom and the dread without dressing either up. Major League Baseball spends more than $1.5 billion a year on pitchers, the sport's most valuable and most breakable asset, and Passan follows that money with obvious relish. He digs into what persuaded one franchise to commit $155 million to a single arm, and the answer exposes a front office's appetite for risk in unusually plain terms. A contract that size is a bet on a ligament nobody can see, placed by people who know some of those bets will fail.
The incentive chapters make the book's central claim: the sport rewards velocity at the expense of durability, and the reward reaches down to teenagers throwing for radar guns because scouts chase the readings. The kid who touches 90 at fifteen gets the phone calls, and the kid who stays healthy at 84 gets a polite email. Each decision in that chain makes sense on its own terms. Added together, they produce the slow-moving epidemic of the book's framing. The prescriptions are thin, a handful of reasonable suggestions that never add up to a plan a league office could act on.
The reporting also predates the pitch clock and the spread of biomechanics labs through player development, so some of its worries read like dispatches from several seasons back. The epidemic framing carries a cost of its own. When every torn ligament becomes evidence of systemic failure, the pitchers who throw hard and stay healthy get treated as flukes, and a group that includes Verlander deserves closer study than the book gives it.
If The Athletic's piece caught your attention, The Arm makes a worthwhile companion to it. Spend your time on the chapters about money and youth pitching, where Passan's argument does its real work and where the Verlander and Scherzer plea starts to look like survivor testimony. Skim the medical history if you already know the Tommy John story, and read the prescriptions knowing the game has rewritten its rules since the reporting. Keep one question with you as you go: what would a team have to be paid for before it let a starter throw the seventh inning again? Whoever answers that decides whether the starter gets saved.